Qualigen Therapeutics (NASDAQ:QLGN) stock is falling on Monday as the clinical-stage therapeutics company’s shares come off of a massive rally on Friday.
That Friday rally resulted in shares of QLGN stock closing out normal trading hours up 109.2%. This came alongside heavy trading, with more than 420 million units traded. For comparison, its daily average trading volume is about 12.5 million shares.
The rally of QLGN stock happened after the company secured new funding. Qualigen Therapeutics sold a Senior Note worth $2 million to an investor. It has a maturity date of July 8, 2025.
To accompany this, Qualigen Therapeutics also changed its board of directors. It removed four members and replaced them with three new members as a condition of the Senior Note sale.
QLGN Stock Movement on Monday
Qualigen Therapeutics isn’t seeing nearly as much trading activity on Monday. This has roughly 3 million units on the move as of this writing. It’s also worth noting that its float is 9.59 million shares.
QLGN stock is down 21.9% as of Monday morning. The company’s shares closed out Friday down 21.1% year-to-date, even after its rally.
Investors on the lookout for more of the most recent stock market stories are in luck!
We have all of the hottest stock market news traders need to know about on Monday! A few examples include what’s happening with shares of Trump Media & Technology (NASDAQ:DJT), DatChat (NASDAQ:DATS) and the biggest pre-market movers this morning. All of this is ready at go at the links below!
More Monday Stock Market News
- Why Is Trump Media & Technology (DJT) Stock Up 48% Today?
- Why Is DatChat (DATS) Up 104% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
